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One of the clearest functions of the gutmicrobiota in humans is resistance to colonization by enteric
bacterial pathogens. Reconstitution of the microbiota offers an exciting therapeutic approach, but
great challenges must be overcome.We are all covered by and filled with bacteria. The first decade of
sequence-based exploration of the human microbiome has es-
tablished the importance of this dense and diverse ecosystem
that we all carry. Entire fields of biology, such as physiology,
immunology, and behavior, are in the process of realigning to
account for the effects of the microbiota within their existing in-
tellectual frameworks. In enteric infectious diseases, where the
microbiota was generally believed to serve as a physical barrier
to pathogens, our understanding of microbiota-mediated resis-
tance has evolved considerably. It is now clear that the micro-
biota are active participants in preventing and sometimes in
driving disease, depending on the state of the system. Work in
the field has been driven by the idea that, if beneficial missing
microbes are added back to the intestine, it may force out the of-
fending microbes, rebalance the system, and prevent disease.
Targeted approaches to rehabilitating the intestinal ecosystem,
with fully defined indications, therapeutics, and diagnostics,
may still be years away, but the remarkable success of early trials
treating recurrent Clostridium difficile infection by reconstitution
of the gut microbiota is cause for measured but realistic hope.
Here, we will survey the known functions of the gut microbiota
in defense against enteric infectious diseases with a focus on
C. difficile, andwewill address some of themajor challenges fac-
ing those who hope to target the gut microbiota for therapy.
The Gut Microbiota
Germ-free laboratory animals can survive and reproduce in a
sterile environment; however, the realities of life on a microbe-
dominated planet led to the co-evolution of animals with bacteria
(McFall-Ngai et al., 2013). Ever since the evolution of the
coelomate digestive tract, microbial populations have co-
evolved within the intestines of animal hosts to form a complex
ecosystem: many bacterial taxa and their phages intermingle
with a wide array of viruses, and a smaller number of fungi and
archaea. The presence and abundance of protists and nema-
todes among the microbiota are likely to vary between popula-
tions, in part based on access to healthcare and local sanitation
standards.
Althoughmicrobiologists have been isolating and studying gut
bacteria since the beginnings of the discipline (Rajilic-Stojanovic1326 Cell 163, December 3, 2015 ª2015 Elsevier Inc.and de Vos, 2014), it is fair to say that pathogenic bacteria have
received greater attention and are better understood than bacte-
rial species that comprise the microbiota (Box 1). In the 1950s,
antibiotics coupled with gnotobiotic mouse-rearing techniques
led to the loss-of-function studies that established the func-
tional importance of the microbiota in resistance to infections.
During this period, it became clear that susceptibility to infection
varied between hosts and that antibiotics can sensitize hosts to
infection. In the 1970s, investigators determined the density of
Enterococci and Enterobacteriaceae following various antibiotic
treatments and demonstrated the importance of commensals in
controlling human infections (Littman and Pamer, 2011; Smith
et al., 2007).
Prior to the wide application of second-generation
sequencing technology to analyze the microbiota, David Rel-
man’s group performed a seminal study characterizing the
colonic microbiota of three healthy individuals by cloning and
sequencing 13,355 bacterial 16S rRNA gene sequences.
They found that many of the bacteria had never been culti-
vated, that most of the sequences derived from species had
never been associated with human disease, and that each in-
dividual harbored a distinct colonic microbiota (Eckburg et al.,
2005). In the last 10 years, high-throughput sequencing has
prompted the adaptation of tools from microbial ecology to
profile the entire gut microbiota population. This work has
determined that the gut microbiota comprises hundreds of
strains, the majority of which come from just two bacterial
phyla: the Bacteroidetes and Firmicutes. Differences in micro-
biota composition have been noted between body sites and in-
dividuals and between cultures around the world. Knowledge
of baseline compositions of the microbiota has linked changes
in composition to phenotypes in laboratory models and pathol-
ogy in humans. Infectious diseases, particularly hospital-ac-
quired infections that follow antibiotic treatment, represent
one of the clearest linkages between changes in the microbiota
and health.
We will review four major functions of the microbiota that are
relevant to bacterial infectious disease: direct inhibition, barrier
maintenance, immune modulation, and metabolism (Figure 1).
These functions all contribute to colonization resistance, defined
Figure 1. Colonization Resistance
The gut microbiome contributes to colonization resistance through at least
four inter-related functions. (1) Direct inhibition of neighboring bacteria via the
production of toxic compounds. (2) Maintenance of the mucus barrier and un-
derlying intestinal epithelium. (3)Regulationof the immune response. (4)Efficient
utilization of host nutrients, such as mucus polysaccharides, by commensals
may serve to limit the expansion of less well-adapted invading microbes.
Box 1. Microbes, Hosts, and Damage
Terminology becomes complicated when incorporating themicrobiota
into microbial pathogenesis, which has focused narrowly on inter-
actions between exogenous pathogens and hosts. The damage-
response framework proposed by Pirofsky and Casadevall, which
considers only microbes, hosts, and damage, is a method of fully inte-
grating the microbiota into infectious disease (Casadevall and Pirofski,
2003, 2015). The source of damage can be microbes or host. Rather
than defining individual microbes as pathogens, mutualists, or com-
mensals, the damage-response framework focuses on the outcome
of interactions between microbes and host. The state of the host
becomes a function of all interactions with its microbes, resulting in
net benefit, damage, or indifference. This allows the incorporation of
host inflammatory feedforward loops that cause damage and exacer-
bate some acute infections (Stecher et al., 2007). The damage-
response framework also pairs nicely with emerging concepts from
immunology, such as disease tolerance, which is defined as host re-
sponses to infection that prevent damage while not directly lowering
levels of the offending microbe (Medzhitov et al., 2012). Approaches
that focus on outcomes rather than strict classification of microbes
will be especially important in determining the roles of microbiota
members in chronic diseases such as inflammatory bowel disease.
The neutral term ‘‘microbiont,’’ defined as any microbe living inside a
host, has been proposed as an alternative to traditional host-centric
classifications of microbes (Miles et al., 2015).as the native ability of a host to suppress invasion by exogenous
microorganisms (Stecher et al., 2013).
Direct Inhibition
Bacteria produce myriad bioactive small molecules and have
long been the primary source of antibiotic candidates for the
pharmaceutical industry (Milshteyn et al., 2014). One example
is antimicrobial peptides, the bacteriocins, which selectively kill
and inhibit the growth of competing bacteria (Kommineni et al.,
2015). A computational prediction of biosynthetic gene clusters
in the human microbiota identified >3,000 candidate clusters,
including many newly annotated antimicrobial peptides, sug-
gesting that these molecules may play a major role in shaping
the population structure of the microbiota (Donia et al., 2014).
Bacteria alsoproduce growth inhibitorymolecules in secondary
metabolism through modification of non-toxic host molecules,
whichhas thepotential forwidesystemiceffects (Box2).Bileacids
are one such example. They are produced in the liver and are
secreted into the intestine in milligram quantities, where they are
modified by the gut microbiota into dozens of different secondary
bile acids, eachwith its ownunique spectrumof chemical andbio-
logical activities (Devlin and Fischbach, 2015; Ridlon et al., 2006).
Secondarybile acid production is drastically reduced by antibiotic
treatment, after which mice and humans are susceptible to
C. difficile infection (Buffie et al., 2015; Theriot et al., 2014;
Weingarden et al., 2014). Reconstitution of antibiotic-treated
mice with C. scindens, a bacterium capable of producing sec-
ondary bile acids, was sufficient to restore secondary bile acid
levels and reduce C. difficile burden. Furthermore, levels of
C. scindens were negatively correlated with C. difficile infection
in antibiotic-treated hematopoietic stem cell transplant pa-
tients, suggesting that a similar mechanism may contribute to
C. difficile resistance in humans (Buffie et al., 2015).Barrier Maintenance
Gut bacteria facilitate their own sequestration within the intestine
by regulating the strength of the intestinal barrier. Themicrobiota
are restricted to the intestinal lumen by a mucus layer that over-
lays the intestinal epithelium and separates the microbiota from
the patrolling immune cells of the intestinal lamina propria. Treat-
ment of mice with antibiotics reduces the thickness of themucus
layer and results in increased contact between the underlying in-
testinal epithelium and gut bacteria (Wlodarska et al., 2011).
Exposure to bacterial products is sufficient to stimulate mucus
synthesis in germ-free mice (Johansson et al., 2015; Petersson
et al., 2011), and alterations to host diet were sufficient to reduce
the thickness of the mucus layer, further emphasizing the impor-
tance of microbial metabolism to barrier maintenance (Earle
et al., 2015). Maintenance of the mucus barrier may be relevant
clinically, as defects in mucus permeability have been observed
in mouse mutants susceptible to colitis (Johansson et al., 2014).
The microbiota directly affects the health of underlying intestinal
epithelial cells by producing short-chain fatty acids (SCFAs),
which are a primary nutrient for the colonic epithelium. De-
creases in SCFAs may result in degradation of the epithelial bar-
rier. In the absence of a strong epithelial barrier, Fusobacterium
necrophorum and Bacteroides fragilis, common species among
the microbiota, cause abscesses and tissue infections.
Immune Maturation and Inflammation
One of the first demonstrations that individual bacteria of the mi-
crobiota contribute to immune development came from studies
with Bacteroides fragilis, which demonstrated that monocoloni-
zation of germ-free mice promoted development of CD4 T lym-
phocytes (Mazmanian et al., 2005). Subsequent studies have
demonstrated that murine intestinal bacterial species promoted
the differentiation of CD4 T cells into Th17 cells (Ivanov et al.,
2009). Th17 cells can contribute to colonization resistance
against pathogens but also contribute to the development of
autoimmune pathology. Bacteria belonging to the cluster XIVa
Clostridium group are associated with the development of anti-
inflammatory T regulatory cells (Atarashi et al., 2013), as are bac-
terial consortia consisting of Bacteroides species (Faith et al.,Cell 163, December 3, 2015 ª2015 Elsevier Inc. 1327
Box 2. The Microbiota as an Endocrine Organ
Bile acid metabolism by the microbiota has the potential to affect sys-
temic physiology. Bile acids function as signaling molecules through
multiple nuclear hormone receptors and G-protein-coupled receptors
expressed in a variety of tissue types (Zhou and Hylemon, 2014) and
cells of the immune system (Brestoff and Artis, 2013). Secondary bile
acids tend to outcompete primary forms for binding to identified recep-
tors. Therefore, the balance of primary to secondary bile acids has the
potential to regulate signaling through these pathways (Ridlon and
Bajaj, 2015). In addition, C. scindens may convert glucocorticoids
(corticosteroids) to androgens; thus, this one bacterium may affect
the balance of multiple classes of exogenous and endogenous steroid
hormones (Ridlon et al., 2013). Microbial metabolites produced by
spore-forming Clostridia, including bile acids, influence the levels of
serotonin produced by enterochromaffin cells, suggesting that sys-
tem-wide modulation of physiology and behavior may be mediated
by the gut microbiota (Hsiao et al., 2013; Yano et al., 2015). Going for-
ward, it will be important for the developers of orally dosed drug treat-
ments to consider the effects of the microbiota on the bioavailability of
drugs. The variability of the microbiota in the population may underlie
some of the heterogeneity of treatment outcomes observed in clinical
trials (Mani et al., 2014).
Box 3. Infectious Disease Ecology
Our deeper understanding of the microbiome’s impact on the host
forces us to reconsider infectious diseases from the perspective of in-
teractions between species within a complex ecosystem. Infectious
diseases are likely to occur by two major mechanisms: acquisition of
an exogenous bacterium or expansion of an endogenous strain that
causes harm at high levels (so-called pathobionts). C. difficile and
other pathogens are carried asymptomatically in the population, and
the question of how often cases are caused by de novo infection versus
expansion remains a challenging exercise in epidemiology. Acquisition
of a pathogen endemic to a hospital is conceptually similar to an inva-
sive species. A foreign but well-adapted bacterium encounters a favor-
able environment (in this case, the GI tract of a patient made sensitive
through antibiotics) and expands to fill the niche. The process of path-
obiont expansion is similar to the loss of a predator, which allows
expansion of former prey species. Mathematical models inspired by
ecology and environmental engineering are being developed with
increasing sophistication (Bucci and Xavier, 2014; Manor et al.,
2014), and such models will be critical in guiding investigators in
designing experiments in the laboratory and in testing hypotheses
generated from model organisms on human sample sets (Buffie
et al., 2015; Stein et al., 2013).2014). Short-chain fatty acids derived from gut microbiota meta-
bolism maintain the balance of inflammatory and anti-inflamma-
tory T cell subsets (Arpaia et al., 2013; Furusawa et al., 2013;
Smith et al., 2013). Thus, the balance of the bacterial population
structure in the gut and the resulting metabolome have the po-
tential to drive pro-inflammatory or anti-inflammatory responses
to immune stimuli.
The microbiota is also a source of ligands for innate immune
signaling. Treatment with antibiotics increases susceptibility of
mice to dextran sodium sulfate (DSS)-mediated colitis, a pheno-
type that can be rescued by the administration of Toll-like recep-
tor ligands. This suggests that pattern recognition receptor
signaling originating from the microbiota is necessary for protec-
tion against epithelial damage (Rakoff-Nahoum et al., 2004). In-
testinal microbes stimulate innate immune receptors to promote
expression of bactericidal C-type lectins by intestinal epithelial
cells that act directly to suppress bacterial growth (Vaishnava
et al., 2011). Stimulation by intestinal bacteria can also enhance
systemic antiviral responses (Abt et al., 2012; Ganal et al., 2012),
while intestinal viruses can enhance antibacterial immunity (Ker-
nbauer et al., 2014).
Utilization of Nutrients
Host nutrition is the primary source of energy for the gut micro-
biota, and changes in host dietary patterns can result in rapid
changes in the population structure of the microbiota (Carmody
et al., 2015; David et al., 2014). As nutrition shapes population
structure and alters the gut metabolome, it may shift the micro-
biota to a state that is sensitive to infection (Ferreyra et al.,
2014a). The ability to successfully colonize a mouse with a given
bacterial strain has been correlated with abundance of close rel-
atives in the target host (Stecher et al., 2010). These data suggest
that high levels of a particular taxon may shift the gut metabo-
lome to a state that is permissive to growth of closely related
strains due to similar metabolic requirements. The microbiota
can also produce nutrients that directly feed invading microbes.1328 Cell 163, December 3, 2015 ª2015 Elsevier Inc.Bacteroides thetaiotaomicron can cleave sialic acid moieties
from mucin glycan strands and produce high levels of succinate
in mono-colonized gnotobiotic mice. The production of both of
these metabolites by B. thetaiotaomicron increased the burden
of Clostridium difficile in co-colonized mice (Ferreyra et al.,
2014b; Ng et al., 2013). Such syntrophic interactions may be
widespread between pathogens and the microbiota, and they
represent potential targets for treatment (Box 3).
Enteric Infectious Diseases in the Post-microbiome Era
The impact of the full range of medical treatments on the micro-
biota remains largely unexplored. Prophylactic antibiotic admin-
istration often begins at birth, and the average child has many
courses of antibiotics during development. Profiling of themicro-
biota in response to a single course of the commonly used
antibiotic ciprofloxacin revealed that some changes to themicro-
biota were reversible within weeks, while others were permanent
(Dethlefsen and Relman, 2011). Memory effects based on previ-
ous history have also been observed due to diet (Carmody et al.,
2015), shifting of feeding time, (Zarrinpar et al., 2014), and sleep-
wakecycles (Thaisset al., 2014). Theeffectsof diurnal rhythmson
microbiota composition and immunity are likely to be significant,
especially in light of recent reports of diurnal fluctuations in im-
mune cell subsets and expression of immune signaling receptors
in intestinal epithelial cells (Mukherji et al., 2013; Nguyen et al.,
2013; Yu et al., 2013). Models derived from data at single time
points may be missing key biology. All of these variables may
contribute to the development of infectious disease through their
effects on the microbiota and colonization resistance.
Treating Acute Infections
C. difficile is themost prominent microbiont exploiting antibiotic-
mediated injury to the microbiota, with >250,000 cases annually.
Cases ofC. difficile are almost always associated with prior anti-
biotic treatment; thus, it seemed clear from the beginning that
susceptibility to this infection resulted from the loss of protective
microbiota (Britton and Young, 2014). The importance of the mi-
crobiota is reflected in the ability of 16S sequencing data alone
to distinguish between C. difficle-positive diarrhea, C. difficile-
negative diarrhea, and controls (Schubert et al., 2014). If there
were any doubts about the ability of microbiota reconstitution
to cure recurrent C. difficile infection, they were put to rest with
a randomized, controlled clinical trial of fecal microbiota trans-
plantation (FMT) demonstrating >90% effectiveness, compared
to 30% for conventional antibiotic treatment (van Nood et al.,
2013). A recent meta-analysis suggests a cumulative cure rate
of 89% in immunocompromised patients (Kelly et al., 2014).
Mechanistic correlation between mouse and man came from
an FMT study in humans that examined levels of bile acids
during treatment, which found that levels of growth-inhibitory
and spore-germination-inhibitory secondary bile acids were
inversely correlated with sensitivity to C. difficile (Weingarden
et al., 2014).
Thesedata suggest that FMT represents a viable treatment op-
tion for patients with recurrentC. difficile. A fecal sample, banked
before hospitalization for surgery or other planned interventions
that involve antibiotics, may provide amethod of preventing hos-
pital-acquired infections while ensuring replenishment of the pa-
tient’s own personalized microbiota. Such an approach would
require an infrastructure of service labs to become economically
viable. The relative effectiveness of donor stool transplants (het-
erologous) versus self-stool transplants (autologous) has not
been tested, and it is possible that undesirable phenotypes
may be transferred from donors to recipients (Alang and Kelly,
2015). The stability of the transferred microbiota over time is
also unclear. Follow-up studies are beginning to appear that sug-
gest that post-FMT variance in population structure of recipients
is not significantly elevated over normal baseline variance in the
donor (Fuentes et al., 2014; Weingarden et al., 2015).
Given the heterogeneous nature of fecal samples, resistance
from clinicians treating chronically ill patients, and regulatory un-
certainty,work has focusedondefining themicrobes responsible
for colonization resistance versus C. difficile. Multiple labs have
identified commensal microbes that confer resistance to
C.difficile in germ-free (Reeveset al., 2012) andantibiotic-treated
mice (Buffie et al., 2015; Lawley et al., 2012). Two of these studies
identified strains from clostridial cluster XIVa as sufficient to
reduce C. difficile burden. C. scindens, assigned to cluster
XIVa, has thepotential todirectly inhibitC.difficilegrowth through
productionof growth-inhibitory andspore-germination-inhibitory
secondary bile acids. Thus,C. scindens could form the base of a
consortium designed to inhibit C. difficile. A mix of 17 clostridial
strains—12 from cluster XIVa, including an isolate of
C. scindens—induced the development of anti-inflammatory T
regulatory (Treg) cells in mice and reduced colitis (Atarashi
et al., 2013), as have combinations of Bacteroides (Faith et al.,
2014). Inclusion of such strains could potentially synergize with
C. scindens to reducemorbidity by suppressing thedamage-pro-
ducing inflammation caused by C. difficile.
In order to return an acutely infected patient to a state of
health, it will be necessary for tailored treatments to both drive
out the offending microbe and fully restore colonization resis-
tance to a broad spectrum of damage-causing microbionts.While it is likely that single strains will be identified that can elim-
inate microbes of interest, it is unlikely that single strains will be
sufficient to fully restore baseline levels of colonization resis-
tance to patients that have lost significant proportions of the di-
versity of their microbiota.
Treating Chronic Dysbiosis
Patients undergoing allogeneic hematopoietic stem cell trans-
plantation, which includes a regimen of antibiotic prophylaxis,
often lose microbiota diversity and become dominated by anti-
biotic-resistant organisms such as Streptococcus viridans,
Enterococcus faecium, and bacteria belonging to the Enterobac-
teriaceae family. And while patients can appear healthy with a
low-diversity microbiota, the loss of microbiota diversity at the
time of stem cell engraftment is associated with markedly
increased mortality over 2 years following transplantation (Taur
et al., 2012, 2014; Ubeda et al., 2010). In these cases, eliminating
the dominant strains and restoring microbiota diversity would be
desirable. In mouse models of E. faecium domination, FMT is
effective in restoring diversity and eliminating E. faceium (Ubeda
et al., 2013).
In order to eliminate unwanted strains in an otherwise healthy
patient, it will be necessary for the donor microbiota to overcome
the colonization resistance of the host and to expel the offending
strain. This may not be possible in the absence of a treatment to
lower colonization resistance. Colonization of germ-free mice
with B. fragilis renders mice highly resistant to subsequent chal-
lenge with the same B. fragilis strain; however, mice mono-colo-
nized with B. fragilis were not resistant to colonization by other
closely related Bacteroides species. Furthermore, in these ex-
periments, B. fragilis was neither expelled nor even reduced in
CFU burden (Lee et al., 2013). These data suggest the existence
of multiple distinct niches for closely related bacteria within the
intestine and illustrate the challenges faced by prospective mi-
crobiome engineers in even simple distillations of the problem.
Further investigations into the basic mechanisms of colonization
and colonization resistance will be crucial to translating these
ideas to the clinic.
Prospects
A simple Internet search returns links to do-it-yourself FMT advo-
cacy web sites, instructional videos, and unsettling images of
home blenders filled with brown liquid. This may have contrib-
uted to a recent decision by the U.S. Food and Drug Administra-
tion to regulate feces as a drug and to require an Investigational
New Drug application for all applications of FMT, except in the
case of severe recurrent C. difficile. FMT outside of a healthcare
setting is not safe and should not be attempted. This statement
may seem at odds with the tremendous success of FMT trials in
treatingC. difficile; however, the donors in these trials were care-
fully selected and screened in a process that eliminated >90% of
candidates, and samples were processed according to Current
Good Manufacturing Practices to minimize the potential of
contamination (Petrof and Khoruts, 2014). A significant risk ex-
ists for transfer of pathogenic microbes and viruses, particularly
in immune-compromised patients.
Engineering the microbiome for health is clearly desirable. As-
sociation studies have identifiedmicrobial candidates underlyingCell 163, December 3, 2015 ª2015 Elsevier Inc. 1329
a diverse array of acute and chronic diseases. A major challenge
going forward will be to determine efficient, minimally invasive
methods of colonizing patients, coupled with the elimination of
unwanted resident microbes. Methods of colonization may arise
from studies aimed at understanding the phenomena that
contribute to the stability of the microbiota (Lahti et al., 2014),
and synthetic biology may uncover genetic modules that in-
crease the efficiency of colonization (Yaung et al., 2015). Future
laboratory investigations should include studies not only of colo-
nization dynamics in germ-free and antibiotic-treated mice, but
also of naive specific pathogen-free mice as well (Kommineni
et al., 2015). Most useful would be the discovery of ‘‘gain-of-
function’’ variants of intestinal bacteria that have the ability to
outcompete and displace closely related strains in antibiotic
naive humans. This will be a great challenge. More than 70 years
of antibiotic chemistry have not produced a small molecule
capable of selectively eliminating bacteria at the strain level;
however, one of the world’s densest microbial ecosystems is
within us and may contain fantastic new molecules and genetic
modules that have evolved for just this purpose. Designer micro-
bial consortia have the potential to reduce the risks involved in
FMT, but the challenges involved in their development are as
great as with any other drug.REFERENCES
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